Nigel J Parr
Overview
Explore the profile of Nigel J Parr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McNicholas D, Parr N
BJU Int
. 2024 Jan;
133(4):487-490.
PMID: 38234225
Introduction: It is challenging to perform prostate biopsy in men with suspicion of prostate malignancy without a rectum to facilitate prostate biopsy. Nevertheless, such patients are presenting at an earlier...
2.
Furze R, Molnar J, Parr N, Ahmad F, Henry Y, Howe D, et al.
Br J Clin Pharmacol
. 2022 Jun;
88(12):5238-5256.
PMID: 35655123
Aims: To improve the tolerability and therapeutic application of histone deacetylase inhibitors (HDACi), by application of an esterase-sensitive motif (ESM), to target pharmacological activity directly to mononuclear myeloid cells expressing...
3.
Piha-Paul S, Hann C, French C, Cousin S, Brana I, Cassier P, et al.
JNCI Cancer Spectr
. 2020 Apr;
4(2):pkz093.
PMID: 32328561
Background: Bromodomain and extra-terminal domain proteins are promising epigenetic anticancer drug targets. This first-in-human study evaluated the safety, recommended phase II dose, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the...
4.
Down K, Amour A, Baldwin I, Cooper A, Deakin A, Felton L, et al.
J Med Chem
. 2015 Aug;
58(18):7381-99.
PMID: 26301626
Optimization of lead compound 1, through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clinical candidates...
5.
Sofos S, Walsh C, Parr N, Hancock K
Int Med Case Rep J
. 2015 Feb;
8:29-31.
PMID: 25653561
The ileal conduit for urinary diversion after radical cystectomy is a well-described procedure. Furthermore, parastomal hernias, prolapse, stenosis, and retraction of the stoma have been reported as some of the...
6.
Lucky M, McGuinness L, Floyd Jr M, Parr N
Can Urol Assoc J
. 2015 Jan;
8(11-12):394.
PMID: 25553147
No abstract available.
7.
Lucky M, Murthy K, Rogers B, Jones S, Lau M, Sangar V, et al.
BJU Int
. 2014 Jul;
115(4):595-8.
PMID: 25060513
Objectives: To review outcomes of the treatment of carcinoma in situ (CIS) of the penis at a large supra-regional penile cancer network, where centralisation has permitted greater experience with treatment...
8.
Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry M, et al.
Blood
. 2013 Dec;
123(5):697-705.
PMID: 24335499
The bromodomain and extraterminal (BET) protein BRD2-4 inhibitors hold therapeutic promise in preclinical models of hematologic malignancies. However, translation of these data to molecules suitable for clinical development has yet...
9.
Tang V, Clarke L, Gall Z, Shanks J, Nonaka D, Parr N, et al.
BJU Int
. 2013 Sep;
114(3):340-3.
PMID: 24053106
Objective: To assess the role of centralized pathological review in penile cancer management. Materials And Methods: Newly diagnosed squamous cell carcinomas (SCC) of the penis, including squamous cell carcinoma in...
10.
Ekwueme K, Simpson H, Zakhour H, Parr N
BJU Int
. 2013 May;
111(8):E365-73.
PMID: 23714648
Objectives: To determine the incidence of prostate cancer (PCa), and pathological grade and location of PCa, using a modified transperineal template-guided saturation biopsy (TTSB). To compare the acute urinary retention...